aTYR PHARMA (ATYR) Total Non-Current Liabilities (2014 - 2016)

aTYR PHARMA (ATYR) has reported Total Non-Current Liabilities for 3 consecutive years, with $14.1 million the latest figure, recorded in Q1 2016.

• For the quarter ending Q1 2016, Total Non-Current Liabilities fell 91.03% year-over-year to $14.1 million; the trailing twelve-month figure through Mar 2016 stood at $14.1 million (down 91.03% YoY), and the FY2015 full-year result was $14.1 million, down 87.38% from the prior year.
• Total Non-Current Liabilities grew to $14.1 million in Q1 2016 per ATYR's latest filing, from $14.1 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $157.5 million in Q1 2015 and bottomed at $11.6 million in Q3 2015.
• Historically, Total Non-Current Liabilities has averaged $53.6 million across 3 years, with a median of $14.1 million in 2015.
• The sharpest annual moves came in 2015 and 2016: Total Non-Current Liabilities plunged 87.38% in 2015, then tumbled 91.03% in 2016.
• Over 3 years, Total Non-Current Liabilities stood at $111.3 million in 2014, then slumped by 87.38% to $14.1 million in 2015, then gained by 0.58% to $14.1 million in 2016.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $14.1 million, $14.1 million, and $11.6 million for Q1 2016, Q4 2015, and Q3 2015 respectively.